Modular Medical Regains Compliance with Nasdaq Minimum Bid Price Requirement
Rhea-AI Summary
Modular Medical (NASDAQ:MODD) announced it has regained compliance with the Nasdaq Capital Market's minimum bid price requirement. As of April 14, 2026, the company evidenced a closing bid price above $1.00 for 10 consecutive trading days, satisfying Nasdaq Marketplace Rule 5550(a)(2).
Nasdaq has advised that the matter is considered closed.
AI-generated analysis. Not financial advice.
Positive
- Regained Nasdaq compliance as of April 14, 2026 after meeting the minimum bid-price test
- Nasdaq considers the matter closed, removing immediate delisting risk tied to the prior deficiency
Negative
- None.
News Market Reaction – MODD
On the day this news was published, MODD gained 2.99%, reflecting a moderate positive market reaction. Argus tracked a peak move of +32.2% during that session. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $834K to the company's valuation, bringing the market cap to $28.72M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
While MODD was down 2.7%, sector peers on the momentum scanner like VVOS (-11.92%) and IINN (-5.51%) also moved lower, with median peer move around -8.7%, indicating broader pressure alongside today’s compliance update.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 09 | Regulatory clearance | Positive | -1.6% | FDA 510(k) clearance for Pivot tubeless insulin patch pump enabling U.S. sales. |
| Mar 26 | Reverse stock split | Negative | -9.8% | 1-for-30 reverse split to increase share price to meet Nasdaq bid rule. |
| Mar 03 | Equity offering | Positive | +7.0% | Public offering of shares and warrants raising about $12.0M gross proceeds. |
| Feb 04 | Operational milestone | Positive | -4.4% | Start of validation production lots for Pivot patch pump components. |
| Dec 31 | Nasdaq extension | Neutral | +0.6% | 180-day extension to regain compliance with Nasdaq minimum bid price rule. |
Recent positive operational and regulatory milestones have often seen mixed or negative next-day price reactions, while financing and structural actions showed more aligned moves.
Over the last several months, Modular Medical has progressed its Pivot insulin patch pump from manufacturing validation to FDA 510(k) clearance on Apr 9, 2026, yet those milestones saw next-day moves of -4.36% and -1.57%. Capital and listing actions have been significant: a $12.0M offering on Mar 3, 2026 led to a 7.01% gain, while the 1-for-30 reverse split on Mar 26, 2026 and the earlier 180-day Nasdaq bid-price extension produced declines or modest moves. Today’s regained compliance follows that sequence of listing-focused steps.
Market Pulse Summary
This announcement confirms that Modular Medical regained compliance with Nasdaq’s $1.00 minimum bid price rule after maintaining the threshold for 10 consecutive trading days. It caps a sequence of listing-focused steps, including a 1-for-30 reverse split and an earlier 180-day extension. In context of recent milestones like FDA 510(k) clearance for the Pivot pump, investors may watch how sustained trading above compliance levels, overall sector momentum, and future commercial execution data develop.
Key Terms
nasdaq capital market regulatory
minimum bid price regulatory
nasdaq marketplace rule 5550(a)(2) regulatory
AI-generated analysis. Not financial advice.
SAN DIEGO, CA / ACCESS Newswire / April 16, 2026 / Modular Medical, Inc. ("Modular Medical" or the "Company") (NASDAQ:MODD), a leader in innovative, patient-centric insulin delivery, today announced that it has received a letter from the Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it has regained compliance with the Nasdaq Capital Market's minimum bid price continued listing requirement. The letter noted that, as of April 14, 2026, the Company evidenced a closing bid price of its common stock in excess of the
About Modular Medical
Modular Medical, Inc. (Nasdaq:MODD) is a development-stage medical device company that intends to launch the next generation of insulin delivery technology. Using its patented technologies, the Company seeks to eliminate the tradeoff between complexity and efficacy, thereby making top quality insulin delivery both affordable and simple to learn. Its mission is to improve access to the highest standard of glycemic control for people with diabetes taking it beyond "superusers" and providing "diabetes care for the rest of us."
Modular Medical was founded by Paul DiPerna, a seasoned medical device professional and microfluidics engineer. Prior to founding Modular Medical, Mr. DiPerna was the founder (in 2005) of Tandem Diabetes and invented and designed its t:slim insulin pump. More information is available at https://modular-medical.com.
CONTACT:
Jeb Besser
Chief Executive Officer
Modular Medical, Inc.
+1 (617) 399-1741
IR@modular-medical.com
SOURCE: Modular Medical, Inc.
View the original press release on ACCESS Newswire